Virology Updates: Influenza and Yellow Fever on the Rise
by Robert Buckheit III
February 1, 2017
As we move into the heart of influenza season, data from a recently published study suggests a close link between the start of the seasonal influenza virus epidemic and the weather, as reported in the Journal of Clinical Virology. It was observed over a three-year period that the first outbreaks of the flu appeared in close proximity with the first "cold spell" of the winter season. It was hypothesized that the decrease in temperature to levels below freezing, in combination with reduction in humidity, resulted in an increased frequency of influenza cases. These data are not entirely novel, as it has been known that aqueous droplets from coughing and sneezing travel more effectively in cold, low humidity environments. However, these results could help provide guidance to public health organizations as they attempt to control and predict when seasonal epidemics might appear. Other respiratory virus infections, such as those caused by respiratory syncytial virus and coronavirus also exhibited a temperature dependent shift in incidence rates.
The CDC tracks cases of influenza throughout the season, and the 2017 incidence rate currently falls within the seasonal baseline; however, the flu season is still reaching its peak and there is evidence that the incidence rate may soon surpass the epidemic threshold. The current 2016-2017 season has a higher incidence rate of influenza-life illness (ILI) compared to last year, but the incidence rate is reduced relative to the 2014-2015 influenza season. Most laboratory confirmed cases have been observed in patients older than age 65, with all other age demographics having similar incidence rates. The majority of cases observed have been for influenza virus type A. These data highlight the need for high levels of influenza vaccination as we reach the peak in the seasonal flu epidemic in the United States, to protect those most at risk for influenza infection associated morbidity and mortality. Separately, the World Health organization is calling for increased vigilance against avian influenza virus, with 24 countries in the WHO European Region reporting outbreaks of highly pathogenic avian influenza A (H5N8) since June 2016.
In other seasonal epidemic news, Brazil has seen an alarming increase in the number of cases of yellow fever, specifically in the Minas Gerais region of Brazil. As of January 30th, more than 100 cases of yellow fever have been reported with 40 deaths out of 97 total cases reported in Minas Gerais. This is the largest outbreak of yellow fever in Brazil since 2000 and the WHO has reported that they expect the mosquito borne disease to spread to other Brazilian states. Similar to zika virus, the yellow fever virus is carried by the Aedes aegypti mosquito and there are fears that the virus could be carried by this vector into more densely populated urban areas.
ImQuest BioSciences has extensive experience in the development of antiviral agents, having performed services for clients that have successfully resulted in INDs for the prevention of viral infection. The core of our antiviral team has worked together for over two decades, and has broad experience in the discovery and development of products to treat and prevent infection by a range of viruses, including influenza and other respiratory viruses, such as parainfluenza virus, respiratory syncytial virus, rhinovirus, measles and adenovirus. We also have services for emerging and mosquito-born viruses, such as yellow fever, dengue, chikungunya and zika virus. Scientists at ImQuest were involved in many of the original antiviral screening programs for HIV inhibitors, and we possess significant expertise for drug discovery programs for HBV and HCV, as well for herpes viruses, including HSV-1 and-2, cytomegalovirus and varicella zoster virus.
Let ImQuest help with your antiviral product development, and take advantage of our preclinical expertise and guidance. Contact us to learn more about our antiviral services and ways that we can enhance the success of your drug development program.Return to the Blog